Abstract: A biological state estimating apparatus includes a pair of electrocardiographic electrodes, a photoplethysmographic sensor, and a controller that includes a peak detecting section, a pulse transmission time measuring section, a correlation information storing section, and a biological state estimating section. The electrocardiographic electrodes detect an electrocardiogram signal and the photoplethysmographic sensor, which has light-emitting and light-receiving elements, detects a photoplethysmogram signal. The controller detects peaks of the electrocardiogram and photoplethysmogram signals and determines a pulse transmission time from the time difference between the respective peaks of the photoplethysmogram and the electrocardiogram signal. Memory stores information determined in advance based on the relationship between pulse transmission time and biological state.

Abstract: The system enables a subject himself to decide on a proper remedial measure, without obtaining particular instruction directly from a medical professional, by providing an advice corresponding to a decision criteria of a plurality of classifications (3x4=12) stored in the storage unit, based on a plurality of autonomic nerve function age ranks and a plurality of autonomic nerve function age ranks A screening system for fatigue and stress has a storage unit which, during screening for fatigue and stress, stores master data composed of reference values for each age, a decision unit which decides by comparing a measurement data obtained by electrocardiogram and pulse wave measurement of the subject with the reference value, and outputs a result of decision classified into the plurality of classifications, and a computing unit which receives the decision results, and calculates autonomic nerve function age ranks, wherein the decision means has an autonomic nerve decision unit which decides autonomic nerve strengt

Abstract: A biological state estimating apparatus includes a pair of electrocardiographic electrodes, a photoplethysmographic sensor, and a controller that includes a peak detecting section, a pulse transmission time measuring section, a correlation information storing section, and a biological state estimating section. The electrocardiographic electrodes detect an electrocardiogram signal and the photoplethysmographic sensor, which has light-emitting and light-receiving elements, detects a photoplethysmogram signal. The controller detects peaks of the electrocardiogram and photoplethysmogram signals and determines a pulse transmission time from the time difference between the respective peaks of the photoplethysmogram and the electrocardiogram signal. Memory stores information determined in advance based on the relationship between pulse transmission time and biological state.

Abstract: Ratios of measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a subject to measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a healthy subject are calculated, and the glucose ratio, the citrate ratio, and the cis-aconitate ratio are used to evaluate and/or assess fatigue. Similarly, an isocitrate ratio, a succinate ratio, a malate ratio, and a lactate ratio are calculated, and these ratios are used together with the three ratios to evaluate and/or assess fatigue. This makes it possible to objectively and easily diagnose and evaluate fatigue.

Abstract: The present invention provides a method and device of quantitatively or qualitatively examining and diagnosing chronic fatigue syndrome (CFS) by: irradiating a sample derived from an examinee or other animal with light having a wavelength in a range of 400 nm to 2500 nm or a wavelength in part of the range; detecting reflected light, transmitted light, or transmitted and reflected light to obtain an absorption spectral data; and analyzing absorbance at all measurement wavelengths or at specific wavelengths in the absorption spectral data by using an analytical model prepared beforehand.

Abstract: The present invention provides a method of determining whether or not a subject is affected with chronic fatigue syndrome (CFS) comprising: measuring, in a biological sample from the subject, an expression level of a transcript of at least one gene respectively from at least two gene groups selected from six specific gene groups; calculating a value representing a deviation of the measured expression level based on an expression level of a transcript of the corresponding gene in a population of healthy subjects; obtaining an average of the value(s) representing a deviation; and determining whether or not the subject is affected with CFS by using the average.

Abstract: An object of the present invention is to provide apparatuses for examining/diagnosing clinical disease of cancer, systemic lupus erythematosus (SLE), or antiphospholipid antibody syndrome. Blood, blood-derived component, urine, sweat, nail, skin, or hair is irradiated with light having a wavelength of 400 to 2,500 nm or a part of the range, of which the reflection light, the transmission light, or the transmission reflection light is then detected to give spectroscopic absorbance data, and afterward a previously prepared analysis model is used to analyze the absorbance over the whole wavelengths or at a specific wavelength for the measurement to allow the achievement of the object.

Abstract: The present invention is a method and an apparatus for examination/diagnosis of lifestyle related disease, wherein the test sample from a human or other animal subject is irradiated with light having a wavelength region of a region of 400 nm-2,500 nm or a part of the region, of which the reflection light, the transmission light, or the transmission reflection light is then detected to give spectroscopic data of absorbance, and afterward a previously prepared analysis model is used to execute an analysis of the absorbance at the whole or specific wavelength used for the measurement.

Abstract: A method of judging fatigue, which comprises judging fatigue by using, as an index, a value obtained by quantitatively analyzing an adenine nucleotide in a sample to be measured.

Abstract: The present invention provides a method and device of quantitatively or qualitatively examining and diagnosing chronic fatigue syndrome (CFS) by: irradiating a sample derived from an examinee or other animal with light having a wavelength in a range of 400 nm to 2500 nm or a wavelength in part of the range; detecting reflected light, transmitted light, or transmitted and reflected light to obtain an absorption spectral data; and analyzing absorbance at all measurement wavelengths or at specific wavelengths in the absorption spectral data by using an analytical model prepared beforehand.

Abstract: The present invention provides a method for easily and quantitatively evaluating a degree of fatigue of a human being, a kit therefor, and an application thereof. Specifically, by measuring a concentration of amino acid in plasma taken from a subject, the degree of fatigue of the subject in daily life can be easily and quantitatively evaluated. Furthermore, an in vivo anti-fatigue effect of an anti-fatigue substance and that of an anti-fatigue food product can be measured.

Abstract: The present invention provides a method for evaluating the degree of fatigue of a human body. The evaluation method of the present invention is characterized by evaluating the degree of fatigue of a human body by using, as an index, change in waveform of a pulse wave, particularly acceleration pulse wave.

Abstract: The present invention provides a labelled acyl-L-carnitine, which is an acyl-L-carnitine, a salt thereof or a derivative thereof, of which carbon group is labelled with a radionuclide or a stable isotope. It is possible to diagnose human diseases falling under acyl-carnitine metabolic syndrome, or human diseases due to structural/functional disorder of the brain by measuring the behavior of the labelled acyl-L-carnitine in various tissues or a biological sample from a subject administered with one or more kinds of the labelled acyl-L-carnitines.

Abstract: A method for treating Acylcarnitine Metabolic Dysfunction Syndrome comprising administering an acylcarnitine or a pharmacologically acceptable salt thereof orally or parenterally is disclosed. The acylcarnitine may be acetylcarnitine, propionylcarnitine, butyrylcarnitine, isobutyrylcarnitine, valerylcarnitine, isovalerylcarnitine or hexanoylcarnitine.